N4P has provided an update on its Nuvec® optimisation programme and proof of concept work involving COVID-19. Interestingly, delays imposed by the Pandemic lockdown presented an opportunity for the Group
Further to the Company’s announcement on 16 April 2020, N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, provides an update on its patent application for Nuvec®, filed
N4P has announced the raising of additional development capital amounting to c.£2.03m (gross) from a placing of c.50.7m new ordinary shares at a price of 4.0p each.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update. Exclusive to Share Talk, here
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that it has filed a new UK patent application
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, provides an update on the Company’s annual general meeting (“AGM”),
Further to the Company’s announcement on 25 March 2020, N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update. Exclusive to Share Talk, here
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update. Exclusive to Share Talk, here
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update. Exclusive to Share Talk, here
